GLP-1 Weight Loss Medications Explained Simply

In 2022, about 13 million Australian adults were living with overweight or obesity — roughly 66% of adults. That’s a huge reason why interest in GLP-1 weight loss treatment has surged across Australia. If you’ve heard people talking about Ozempic, Wegovy or Mounjaro and wondered whether these medicines are a miracle, a trend, or a legitimate obesity treatment, you’re asking exactly the right question. The short answer is this: they are real medicines with real benefits, real limits, and real risks — and understanding how GLP-1 works makes the whole conversation much clearer. The Australian Institute of Health and Welfare’s overweight and obesity summary and the Australian Government’s overview of overweight and obesity show just how relevant this issue has become for Australians.

That’s what this guide is here to do. We’re going to strip away the hype and explain, in plain English, what GLP-1 medications actually do inside the body, why they can help with sustainable weight loss, which medicines are used as weight loss medication in Australia, who may be eligible, and what safety points matter most. Think of this as the “finally, someone explained it properly” version. The TGA describes GLP-1 and dual GIP/GLP-1 medicines as high-profile newer classes used for type 2 diabetes and/or obesity, and several are now marketed in Australia.

This article is general information only and isn’t a substitute for personal medical advice from a doctor who knows your history.

First up: what does GLP-1 actually mean?

GLP-1 stands for glucagon-like peptide-1. It’s a hormone your body naturally releases after you eat. In simple terms, it helps coordinate what happens next: your brain gets signals about fullness, your pancreas adjusts blood sugar-related hormones, and your digestive system slows down a bit so food leaves the stomach more gradually. Official Australian medicine information for semaglutide and liraglutide describes GLP-1’s role in both glucose regulation and appetite regulation, including effects in the pancreas and the brain.

Here’s the easiest way to think about it: GLP-1 is part of your body’s “we’ve eaten, you can ease off now” system. When that signalling is stronger or lasts longer, people tend to feel fuller, less snacky, and less preoccupied by food. That doesn’t mean hunger disappears completely — and it definitely doesn’t mean the medicine is doing all the work for you — but it can make healthy eating feel far less like a constant internal battle. Official product information for semaglutide, liraglutide and tirzepatide all describe reduced appetite, greater fullness or satiety, and lower food intake as key effects.

So, how does GLP-1 work in the body?

If you want the simple version of how GLP-1 works, it comes down to three main jobs:

• It helps regulate appetite in the brain, increasing feelings of fullness and satiety while lowering hunger.
• It slows stomach emptying, so food moves through the stomach more slowly.
• It supports blood sugar control, including stimulating insulin secretion and lowering glucagon in a glucose-dependent way.

That combination matters. If you feel full sooner, stay full longer, and have fewer cravings, eating less can feel more natural. That’s a big reason these medicines have changed the conversation around modern obesity treatment. They are not classic “appetite suppressants” in the old stimulant sense, and they are not fat burners. They work more by changing the biological signals that influence hunger, satiety and food intake. Official medicine information for liraglutide even notes that weight loss is mainly driven by lower calorie intake, not by an increase in 24-hour energy expenditure.

How GLP-1 weight loss medicines copy that natural system

GLP-1 medicines are designed to mimic or activate the same receptor system as the body’s natural GLP-1 hormone. Semaglutide, the active ingredient in Wegovy, is a GLP-1 analogue that activates the GLP-1 receptor and has effects in the pancreas and the brain. The official Australian product information says semaglutide reduces energy intake, increases satiety and fullness, reduces hunger, and lowers the frequency and intensity of cravings.

Liraglutide, used in Saxenda, works in a similar way. Australian product information says it increases fullness and satiety, lowers hunger and expected food consumption, and causes a minor delay in gastric emptying. In other words, it helps the body create a stronger “that’s enough for now” signal after eating.

Then there’s tirzepatide, used in Mounjaro. This one is slightly different: it’s a dual GIP/GLP-1 receptor agonist, not just a straight GLP-1 receptor agonist. The TGA’s medicine information describes tirzepatide as acting on both GIP and GLP-1 receptors, reducing food intake, regulating appetite, delaying gastric emptying and improving glycaemic control. That’s why people often hear it spoken about in the same breath as GLP-1 medicines, even though technically it’s a broader, dual-action medicine.

GLP-1 weight loss medication in Australia: which medicines are available?

In Australia, the TGA says the medicines in these classes currently marketed include Saxenda (liraglutide) and Wegovy (semaglutide) for chronic weight management, plus Mounjaro (tirzepatide) for both diabetes and chronic weight management. Ozempic is also semaglutide, but it is approved for adults with type 2 diabetes rather than as a dedicated weight-management product.

That distinction matters because there is still a lot of confusion online. People often use “Ozempic” as shorthand for the whole category, but in Australian medicine information, Wegovy is the semaglutide product specifically indicated for chronic weight management, while Ozempic is listed for type 2 diabetes care. If you want the plain-language medicine information, Healthdirect’s Wegovy page and Healthdirect’s Ozempic page are useful starting points.

There are practical differences too. Saxenda is a once-daily injection, while Wegovy and Mounjaro are once-weekly injections. Australian product information shows that all three are started at lower doses and then gradually increased to improve tolerability, especially because stomach-related side effects are more common early on.

Why do people lose weight on these medicines?

The most accurate answer is also the least flashy one: people usually lose weight on these medicines because they help them eat less without fighting themselves as hard. When appetite, fullness and cravings shift, sticking to a reduced-energy eating pattern becomes more doable. Semaglutide’s Australian product information says energy intake during an unrestricted meal was lower with treatment, and liraglutide and tirzepatide product information both describe reduced food intake as part of the mechanism behind weight loss.

This is one reason the phrase sustainable weight loss matters. In real life, many people don’t struggle because they “don’t know what healthy food is.” They struggle because biology pushes back: hunger stays loud, fullness is weak, cravings keep returning, and weight regain can happen fast. GLP-1 medicines can change that biological pushback enough to make healthy habits more sustainable — but they still work best when they’re part of a broader plan, not a replacement for one. The TGA-approved indications for Wegovy, Saxenda and Mounjaro all describe them as adjuncts to a reduced-energy or reduced-calorie diet and increased physical activity.

What kind of results are we talking about?

This is where the internet tends to swing between extremes: either “you’ll lose half your body weight” or “it’s all fake.” Neither is helpful.

In the 68-week STEP 1 trial summarised in Wegovy’s Australian product information, the average weight change was -14.9% with Wegovy versus -2.4% with placebo, and almost 48% of patients achieved at least 15% weight loss. In the 72-week SURMOUNT-1 trial summarised in Mounjaro’s Australian product information, average weight change ranged from -16.0% to -22.5% depending on dose, versus -2.4% with placebo.

Those are average clinical trial results, not promises. Real-world results vary a lot from person to person. Some people lose a substantial amount, some lose more gradually, and some stop because of side effects, cost, access or because the medicine simply doesn’t suit them. That’s why a proper medical review matters more than social media before-and-afters.

Who may be eligible for weight loss medication in Australia?

For adults, the common TGA pattern is this: these medicines may be used for chronic weight management in people with a BMI of 30 or more, or a BMI of 27 or more with at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes, depending on the product. That framework is reflected in Australian medicine information for Wegovy, Saxenda and Mounjaro.

But BMI is not the whole story. Doctors also look at your medical history, current medications, past weight-loss attempts, likely benefits, likely risks, pregnancy plans, mental health factors, and whether medication is clinically appropriate right now. If you want a more Australia-specific breakdown, we’ve covered that in Am I Eligible for Weight Loss Medication in Australia?.

That’s worth stressing, because one of the biggest myths around weight loss medication Australia is that eligibility is just “ask for the injection and see if someone says yes.” Good care doesn’t work like that. A proper consult should look at the whole person, not just the number on the scale. At NextClinic, we approach it that way too: prescribing decisions are based on safety, legality and clinical justification, not convenience alone.

What does treatment actually feel like week to week?

Many people imagine these medicines work overnight. Usually, they don’t. In Australia, product information for Wegovy, Saxenda and Mounjaro all show that treatment generally starts at a low dose and then gradually increases over weeks. That slow escalation is there for a reason: it helps reduce the chance of unpleasant gastrointestinal side effects.

Early on, some people notice that they get full faster, think about food less often, or naturally leave food on the plate. Others mainly notice side effects at first and only later feel the appetite changes. And because the medicines are meant to work alongside lifestyle change, the most helpful question usually isn’t “Has the injection done everything yet?” but “Is this making healthier eating and movement easier to keep doing?”

Common side effects: what’s normal, and what matters?

The most common side effects are gastrointestinal. Australian product information for Wegovy, Saxenda and Mounjaro all list nausea, diarrhoea, constipation and vomiting among the most frequently reported adverse effects, especially during dose escalation.

For many people, these side effects are mild to moderate and improve with time. But “common” doesn’t mean “ignore it.” If vomiting or diarrhoea is severe, dehydration can become a problem. Wegovy’s product information specifically warns that gastrointestinal side effects can contribute to dehydration and worsen kidney function in some people, and tirzepatide information notes reported gastrointestinal reactions and the need for monitoring if symptoms are severe.

That’s why the practical advice matters so much: eat slowly, don’t push past fullness, stay hydrated, and keep your prescriber updated if symptoms are persistent or severe. If you develop significant abdominal pain, repeated vomiting, or feel seriously unwell, get medical advice promptly.

One safety point many people miss: surgery and sedation

The TGA has specifically warned that GLP-1 and dual GIP/GLP-1 medicines can delay gastric emptying, which matters before surgery or procedures involving general anaesthesia or deep sedation. The concern is that standard fasting times may not fully empty the stomach, increasing the risk of inhaling stomach contents. The TGA advises patients to tell their health professionals — including anaesthetists — if they are taking one of these medicines. You can read more in the TGA safety alert on new diabetes and weight loss medicines.

A sexual health detail that deserves more attention

If you’re using Mounjaro (tirzepatide) and you rely on the oral contraceptive pill, this is important. In December 2025, the TGA updated contraception advice for tirzepatide and said reduced effectiveness of oral contraception during treatment initiation or dose escalation could not be ruled out. The current advice is to switch to a non-oral contraceptive or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. The same TGA update also reminds patients that GLP-1 medicines are not recommended during pregnancy. See the TGA’s updated contraception advice for Mounjaro for the full details.

That’s a good example of why self-diagnosing or self-prescribing from the internet is risky. A medicine can be excellent for one health goal and still raise other practical issues that need planning around.

What GLP-1 medicines can’t do

This is the part people often need to hear most.

GLP-1 medicines can help with appetite regulation, calorie intake and weight loss. But they do not permanently “fix” your biology after a few weeks. In a withdrawal study summarised in Wegovy’s Australian product information, people who continued semaglutide after the initial phase kept losing weight, while those switched to placebo regained weight. That’s one reason obesity is increasingly treated as a chronic condition rather than a short-term project.

They also don’t replace the basics of long-term health. Australian medicine indications consistently describe these medicines as an add-on to better nutrition and physical activity, and Australia’s Dietary Guidelines and physical activity guidelines for adults still matter.

So if you’re aiming for sustainable weight loss, the smartest mindset is usually this: let the medicine lower the biological noise, then use that breathing room to build routines you can actually keep.

Some of the most useful habits to work on while treatment is helping include:

• planning regular meals instead of swinging between restriction and overeating
• building an eating pattern that lines up with the Australian Dietary Guidelines
• increasing physical activity in a way that is realistic for your current fitness and health
• keeping regular check-ins with your GP or telehealth doctor so dose, side effects and progress are reviewed properly.

If you’re trying to understand how telehealth scripts fit into that picture, our guides on Can You Get a Script Without a Video Call? and our Online Prescription Service explain how proper online prescribing works in Australia.

Please don’t buy “GLP-1” products from random websites or social media

This is one of the most important Australia-specific warnings right now.

In March 2026, the TGA issued an updated safety advisory after testing confirmed counterfeit imported weight-loss products that claimed to contain GLP-1 ingredients. According to the TGA, several products contained no GLP-1 or GLP-1 analogues at all, despite being labelled that way. The TGA advises Australians to buy prescription medicines only from a local registered pharmacy and not to buy unregistered GLP-1 products via social media or other online platforms. Read the TGA alert on counterfeit weight loss products claiming to contain GLP-1.

In Australia, legitimate GLP-1 medicines are prescription-only medicines and should be used under medical supervision. If a product is being sold like a supplement, patch, drop or miracle oral liquid with no proper prescription process, that’s a major red flag.

Where NextClinic fits in

For Australians exploring obesity treatment or other prescription-based care, telehealth can make the process more accessible — especially if you’re in a regional area, short on time, or simply not keen on sitting in a waiting room. But convenience should never come at the cost of proper medical review. Our view is simple: medication decisions should be made carefully, and a telehealth consult should meet the same professional standards you’d expect anywhere else.

That means asking the right questions, checking whether treatment is actually appropriate, and being willing to say “not yet” or “not this medicine” when that’s the safest call. If you want to keep reading, our article Am I Eligible for Weight Loss Medication in Australia? is a useful next step before booking any consult.

The bottom line

GLP-1 medications matter because they target the biology of hunger, fullness and food intake — not because they offer a magical escape from healthy habits. That’s the real answer to how GLP-1 works. They help many people feel fuller, eat less, reduce cravings and achieve clinically meaningful weight loss, which is why they’ve become such an important part of modern obesity treatment in Australia. But they’re still prescription medicines, they still carry side effects and safety considerations, and they work best as part of a broader long-term plan rather than a quick fix.

So here’s our challenge for you this week: pick one practical step toward more sustainable weight loss. Maybe that’s reading up on the official medicine information, booking a conversation with your GP, reviewing your eating routine, or adding a realistic movement habit you can actually keep. Then come back and tell us in the comments which strategy you chose — and what you noticed after giving it a proper go.

References

• Overweight and obesity, Summary - Australian Institute of Health and Welfare
• New diabetes and weight loss medicines | Therapeutic Goods Administration (TGA)
• Attachment Product information for Wegovy
• AusPAR Attachment 1: Product Information for Saxenda
• Mounjaro | Therapeutic Goods Administration (TGA)
• Wegovy | healthdirect
• Am I Eligible for Weight Loss Medication in Australia? | NextClinic
• Updated contraception advice for Mounjaro (tirzepatide) | Therapeutic Goods Administration (TGA)
• Australian Dietary Guidelines | NHMRC
• Can You Get a Script Without a Video Call? | NextClinic
• Counterfeit weight loss products claiming to contain GLP-1 | Therapeutic Goods Administration (TGA)

FAQs